These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11779569)

  • 1. Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes.
    Gagné JF; Désormeaux A; Perron S; Tremblay MJ; Bergeron MG
    Biochim Biophys Acta; 2002 Feb; 1558(2):198-210. PubMed ID: 11779569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphoid tissue targeting of anti-HIV drugs using liposomes.
    Désormeaux A; Bergeron MG
    Methods Enzymol; 2005; 391():330-51. PubMed ID: 15721390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sterically stabilized liposomes bearing anti-HLA-DR antibodies for targeting the primary cellular reservoirs of HIV-1.
    Bestman-Smith J; Gourde P; Désormeaux A; Tremblay MJ; Bergeron MG
    Biochim Biophys Acta; 2000 Sep; 1468(1-2):161-74. PubMed ID: 11018661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting lymph nodes with liposomes bearing anti-HLA-DR Fab' fragments.
    Dufresne I; Désormeaux A; Bestman-Smith J; Gourde P; Tremblay MJ; Bergeron MG
    Biochim Biophys Acta; 1999 Oct; 1421(2):284-94. PubMed ID: 10518698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting cell-free HIV and virally-infected cells with anti-HLA-DR immunoliposomes containing amphotericin B.
    Bestman-Smith J; Désormeaux A; Tremblay MJ; Bergeron MG
    AIDS; 2000 Nov; 14(16):2457-65. PubMed ID: 11101055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: a proof of concept study in HIV-2287-infected macaques.
    Kinman L; Brodie SJ; Tsai CC; Bui T; Larsen K; Schmidt A; Anderson D; Morton WR; Hu SL; Ho RJ
    J Acquir Immune Defic Syndr; 2003 Dec; 34(4):387-97. PubMed ID: 14615656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
    Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
    Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.
    Sugano M; Egilmez NK; Yokota SJ; Chen FA; Harding J; Huang SK; Bankert RB
    Cancer Res; 2000 Dec; 60(24):6942-9. PubMed ID: 11156394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surface structured liposomes for site specific delivery of an antiviral agent-indinavir.
    Dubey V; Nahar M; Mishra D; Mishra P; Jain NK
    J Drug Target; 2011 May; 19(4):258-69. PubMed ID: 20604740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes.
    Clayton R; Ohagen A; Nicol F; Del Vecchio AM; Jonckers TH; Goethals O; Van Loock M; Michiels L; Grigsby J; Xu Z; Zhang YP; Gutshall LL; Cunningham M; Jiang H; Bola S; Sarisky RT; Hertogs K
    Antiviral Res; 2009 Nov; 84(2):142-9. PubMed ID: 19699239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat.
    Huwyler J; Yang J; Pardridge WM
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1541-6. PubMed ID: 9316870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.
    Mamot C; Drummond DC; Noble CO; Kallab V; Guo Z; Hong K; Kirpotin DB; Park JW
    Cancer Res; 2005 Dec; 65(24):11631-8. PubMed ID: 16357174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of indinavir submicron lipid emulsions loaded with lipoamino acids-in vivo pharmacokinetics and brain-specific delivery.
    Bollam S; Kandadi P; Apte SS; Veerabrahma K
    AAPS PharmSciTech; 2011 Mar; 12(1):422-30. PubMed ID: 21360313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of lipid-indinavir complexes for localization in lymphoid tissues of HIV-infected macaques.
    Kinman L; Bui T; Larsen K; Tsai CC; Anderson D; Morton WR; Hu SL; Ho RJ
    J Acquir Immune Defic Syndr; 2006 Jun; 42(2):155-61. PubMed ID: 16760797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity.
    Wasmuth JC; Lambertz I; Voigt E; Vogel M; Hoffmann C; Burger D; Rockstroh JK
    Eur J Clin Pharmacol; 2007 Oct; 63(10):901-8. PubMed ID: 17690876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery.
    Dou H; Destache CJ; Morehead JR; Mosley RL; Boska MD; Kingsley J; Gorantla S; Poluektova L; Nelson JA; Chaubal M; Werling J; Kipp J; Rabinow BE; Gendelman HE
    Blood; 2006 Oct; 108(8):2827-35. PubMed ID: 16809617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced transdermal delivery of an anti-HIV agent via ethanolic liposomes.
    Dubey V; Mishra D; Nahar M; Jain V; Jain NK
    Nanomedicine; 2010 Aug; 6(4):590-6. PubMed ID: 20093197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes.
    Harding JA; Engbers CM; Newman MS; Goldstein NI; Zalipsky S
    Biochim Biophys Acta; 1997 Jul; 1327(2):181-92. PubMed ID: 9271260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of organ-specific immunoliposomes for delivery of 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in a mouse lung-metastasis model.
    Mori A; Kennel SJ; van Borssum Waalkes M; Scherphof GL; Huang L
    Cancer Chemother Pharmacol; 1995; 35(6):447-56. PubMed ID: 7882453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virological and immunological outcomes in HIV-1-infected Chinese patients treated with a combination of Efavirenz and Indinavir for 48 weeks.
    Li L; Wei FL; Mei S; Feng X; Yao J; Jin X; Cao YZ
    Chin Med J (Engl); 2004 Mar; 117(3):347-52. PubMed ID: 15043771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.